findmyKOL
Clinical trialNCT04230109RecruitingPhase 2Interventional

Sacituzumab Govitecan In TNBC

SponsorMassachusetts General HospitalEnrollment260ER-Negative Breast CancerHER2-negative Breast CancerInvasive Breast CancerPR-Negative Breast CancerTriple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    Neelam Desai, MD
    Recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Sara Tolaney, MD, MPH
    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Laura Spring, MD
    Recruiting
  • Massachusetts General Hospital - North Shore Cancer Center

    Danvers, Massachusetts, United States

    Therese Mulvey, MD
    Recruiting
  • Massachusetts General Hospital at Newton-Wellesley Hospital

    Newton, Massachusetts, United States

    Amy Comander, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →Sacituzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Jul 2020
Primary completion
31 Oct 2028
Completion
31 Oct 2029
Last update posted
2 Jun 2026
Registered enrollment
260
Registry id
NCT04230109
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.